- Sanofi (SNY, Financial) posts a strong Q1 performance, beating earnings and revenue forecasts.
- Analysts forecast a notable upside with a bullish average price target of $63.12.
- GuruFocus estimates reveal a promising GF Value, signaling potential growth.
Sanofi (SNY) showcased a remarkable first quarter, achieving a Non-GAAP EPS of €1.79, which surpassed analyst predictions by €0.12. The pharmaceutical giant reported revenues of €9.89 billion, surpassing expectations by €120 million despite experiencing a 5.4% decline compared to the same period last year. This robust performance was primarily propelled by substantial sales of ALTUVIIIO and Dupixent. The company remains optimistic, reaffirming its positive outlook for future sales and EPS growth.
Wall Street Analysts Forecast
Sanofi SA (SNY, Financial) has garnered attention from analysts, with six offering one-year price targets. The average target price is pegged at $63.12, with high and low estimates of $67.00 and $56.00, respectively. This average target suggests a significant upside potential of 18.92% from the current trading price of $53.08. Investors seeking more extensive estimate details can explore the Sanofi SA (SNY) Forecast page.
Furthermore, the consensus recommendation from seven brokerage firms maintains Sanofi SA's (SNY, Financial) rating at 1.9, reflecting an "Outperform" status. This recommendation scale ranges from 1 to 5, where a score of 1 symbolizes a Strong Buy, and 5 indicates a Sell.
GuruFocus Value Analysis
According to GuruFocus metrics, the projected GF Value for Sanofi SA (SNY, Financial) in the coming year stands at $60.84. This estimation suggests a promising upside of 14.62% from the current price of $53.08. The GF Value represents GuruFocus' assessment of the stock's fair market value, derived from historical trading multiples, past business growth, and future business performance projections. Investors interested in more comprehensive data should visit the Sanofi SA (SNY) Summary page.
